A real ‐world retrospective–prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience
ConclusionIRd might be effective and safe in RRMM pts with an indolent disease, in early lines of treatment, and who proved Len-sensitive, independent of age, and cytogenetic risk. (Source: Cancer Medicine)
Source: Cancer Medicine - April 1, 2024 Category: Cancer & Oncology Authors: Anna Furlan,
Michele Cea,
Laura Pavan,
Monica Galli,
Cristina Clissa,
Silvia Mangiacavalli,
Anna Maria Cafro,
Stefania Girlanda,
Francesca Patriarca,
Claudia Minotto,
Giovanni Bertoldero,
Gregorio Baril à,
Anna Pascarella,
Albana Lico,
Ross Tags: RESEARCH ARTICLE Source Type: research
Effect of CYP2C19 polymorphism on response to bortezomib-based therapy in multiple myeloma patients
CONCLUSIONS: Polymorphism in CYP2C19 enzyme is likely to have an impact on bortezomib treatment response and peripheral neuropathy. The study suggests the role of pharmacogenetics in personalised treatment of MM.PMID:38561047 | DOI:10.1016/j.amjms.2024.03.022 (Source: The American Journal of the Medical Sciences)
Source: The American Journal of the Medical Sciences - April 1, 2024 Category: General Medicine Authors: Lavisha Goel Pooja Gupta Lalit Kumar Thirumurthy Velpandian Archana Singh Kalpana Luthra Yogendra Kumar Gupta Source Type: research
Effect of CYP2C19 polymorphism on response to bortezomib-based therapy in multiple myeloma patients
CONCLUSIONS: Polymorphism in CYP2C19 enzyme is likely to have an impact on bortezomib treatment response and peripheral neuropathy. The study suggests the role of pharmacogenetics in personalised treatment of MM.PMID:38561047 | DOI:10.1016/j.amjms.2024.03.022 (Source: The American Journal of the Medical Sciences)
Source: The American Journal of the Medical Sciences - April 1, 2024 Category: General Medicine Authors: Lavisha Goel Pooja Gupta Lalit Kumar Thirumurthy Velpandian Archana Singh Kalpana Luthra Yogendra Kumar Gupta Source Type: research
Effect of CYP2C19 polymorphism on response to bortezomib-based therapy in multiple myeloma patients
CONCLUSIONS: Polymorphism in CYP2C19 enzyme is likely to have an impact on bortezomib treatment response and peripheral neuropathy. The study suggests the role of pharmacogenetics in personalised treatment of MM.PMID:38561047 | DOI:10.1016/j.amjms.2024.03.022 (Source: The American Journal of the Medical Sciences)
Source: The American Journal of the Medical Sciences - April 1, 2024 Category: General Medicine Authors: Lavisha Goel Pooja Gupta Lalit Kumar Thirumurthy Velpandian Archana Singh Kalpana Luthra Yogendra Kumar Gupta Source Type: research
Cost and value of cancer medicines in a single-payer public health system in Ontario, Canada: a cross-sectional study
We describe temporal trends in expenditure on cancer medicines within the single-payer health system of Ontario, Canada, and the extent of clinical benefit these treatments offer.METHODS: In this cross-sectional study, we identified cancer medicines and expenditures from formularies and costing databases (the New Drug Funding Program, Ontario Drug Benefit Program, and The High-Cost Therapy Funding Program) during 10 consecutive years (April 1, 2012, to March 31, 2022) in Ontario, Canada. For intravenous medicines, we applied the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) to identi...
Source: Cancer Control - March 28, 2024 Category: Cancer & Oncology Authors: Joseph C Del Paggio Rohini Naipaul Scott Gavura Rebecca E Mercer Rachel Koven Bishal Gyawali Brooke E Wilson Christopher M Booth Source Type: research
A phase 1 dose-escalation study of low-dose lenalidomide maintenance post-allogeneic stem cell transplantation for high-risk acute myeloid leukaemia or myelodysplastic syndrome
Bone Marrow Transplantation, Published online: 27 March 2024; doi:10.1038/s41409-023-02195-xA phase 1 dose-escalation study of low-dose lenalidomide maintenance post-allogeneic stem cell transplantation for high-risk acute myeloid leukaemia or myelodysplastic syndrome (Source: Bone Marrow Transplantation)
Source: Bone Marrow Transplantation - March 27, 2024 Category: Hematology Authors: Ray Mun Koo Eric Wong Joanne E. Davis Travis Perera Andrew Lim Rachel M. Koldej David S. Ritchie Source Type: research
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide
Blood Cancer Journal, Published online: 26 March 2024; doi:10.1038/s41408-024-01039-1Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - March 26, 2024 Category: Hematology Authors: Utkarsh Goel Charalampos Charalampous Prashant Kapoor Moritz Binder Francis K. Buadi David Dingli Angela Dispenzieri Amie Fonder Morie A. Gertz Wilson I. Gonsalves Suzanne R. Hayman Miriam A. Hobbs Yi L. Hwa Taxiarchis Kourelis Martha Q. Lacy Nelson Leung Source Type: research
Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis
CONCLUSION: The combination of ofatumumab, HDMP, and lenalidomide was effective and relatively well tolerated in treatment-naive CLL/SLL. Its role in the frontline setting remains unclear given the current available and effective treatment options.FUNDING: The funders had no role in the study.PMID:38508880 | DOI:10.1016/j.clml.2024.02.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 20, 2024 Category: Cancer & Oncology Authors: Julio C Chavez Ariel Grajales Jose Sandoval-Sus Elyce Turba Lisa Nodzon Angimar Uriepero-Palma Mohammad Ammad-Ud-Din Eva Sahakian Rami Komrokji Lubomir Sokol Frederick L Locke Bijal Shah Jeffrey Lancet Eduardo M Sotomayor Mohamed A Kharfan-Dabaja Celeste Source Type: research
Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis
CONCLUSION: The combination of ofatumumab, HDMP, and lenalidomide was effective and relatively well tolerated in treatment-naive CLL/SLL. Its role in the frontline setting remains unclear given the current available and effective treatment options.FUNDING: The funders had no role in the study.PMID:38508880 | DOI:10.1016/j.clml.2024.02.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 20, 2024 Category: Cancer & Oncology Authors: Julio C Chavez Ariel Grajales Jose Sandoval-Sus Elyce Turba Lisa Nodzon Angimar Uriepero-Palma Mohammad Ammad-Ud-Din Eva Sahakian Rami Komrokji Lubomir Sokol Frederick L Locke Bijal Shah Jeffrey Lancet Eduardo M Sotomayor Mohamed A Kharfan-Dabaja Celeste Source Type: research
Selinexor in multiple myeloma
This article provides a review of selinexor, with a focus on available clinical studies involving MM patients and its safety profile. Clinical trials, such as STORM and BOSTON, have demonstrated its efficacy, particularly in combination regimens, showcasing notable overall response rates (ORR) and prolonged median progression-free survival (mPFS). Selinexor's versatility is evident across various combinations, including carfilzomib-dexamethasone (XKd), lenalidomide-dexamethasone (XRd), and pomalidomide-dexamethasone (XPd), with efficacy observed even in triple-class refractory and high-risk patient populations. However, ch...
Source: Expert Opinion on Pharmacotherapy - March 19, 2024 Category: Drugs & Pharmacology Authors: Enrica Antonia Martino Ernesto Vigna Antonella Bruzzese Caterina Labanca Francesco Mendicino Eugenio Lucia Virginia Olivito Annamaria Zimbo Federica Torricelli Antonino Neri Fortunato Morabito Massimo Gentile Source Type: research
Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma
In Mantle Cell Lymphoma (MCL), the role of macrophages within the tumour microenvironment (TME) has recently gained attention due to their impact on prognosis and response to therapy. Despite their low absolute number in MCL tumour tissue, recent findings reveal an association between the levels of macrophages and prognosis, consistent with trends observed in other lymphoma subtypes. M2-like macrophages, identified by markers such as CD163, contribute to angiogenesis and suppression of the immune response. Clinical trials with MCL patients treated with chemoimmunotherapy and targeted treatments underscore the adverse impac...
Source: Frontiers in Immunology - March 19, 2024 Category: Allergy & Immunology Source Type: research
Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data
CONCLUSION: This anchored ITC demonstrated a greater PFS benefit for D-Rd versus VRd in TIE patients with NDMM. In the absence of head-to-head trials comparing D-Rd and VRd, the present trial may help inform treatment selection in this patient population.PMID:38494542 | DOI:10.1007/s12325-024-02807-y (Source: Adv Data)
Source: Adv Data - March 18, 2024 Category: Epidemiology Authors: Brian G M Durie Shaji K Kumar Eric M Ammann Alex Z Fu Shuchita Kaila Annette Lam Saad Z Usmani Thierry Facon Source Type: research
Safety and Effectiveness of Elotuzumab in Japanese Patients with Relapsed/Refractory Multiple Myeloma: A Post-marketing Surveillance Study
Conclusion This all-case post-marketing surveillance study showed that ELd had an acceptable tolerability profile and promising clinical activity in Japanese patients with RRMM.PMID:38494720 | DOI:10.2169/internalmedicine.2487-23 (Source: Internal Medicine)
Source: Internal Medicine - March 18, 2024 Category: Internal Medicine Authors: Fumiya Kaneko Hiroshi Suzuka Tomoaki Yoshino Ryosuke Hinosugi Source Type: research
Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data
CONCLUSION: This anchored ITC demonstrated a greater PFS benefit for D-Rd versus VRd in TIE patients with NDMM. In the absence of head-to-head trials comparing D-Rd and VRd, the present trial may help inform treatment selection in this patient population.PMID:38494542 | DOI:10.1007/s12325-024-02807-y (Source: Adv Data)
Source: Adv Data - March 18, 2024 Category: Epidemiology Authors: Brian G M Durie Shaji K Kumar Eric M Ammann Alex Z Fu Shuchita Kaila Annette Lam Saad Z Usmani Thierry Facon Source Type: research
Safety and Effectiveness of Elotuzumab in Japanese Patients with Relapsed/Refractory Multiple Myeloma: A Post-marketing Surveillance Study
Conclusion This all-case post-marketing surveillance study showed that ELd had an acceptable tolerability profile and promising clinical activity in Japanese patients with RRMM.PMID:38494720 | DOI:10.2169/internalmedicine.2487-23 (Source: Internal Medicine)
Source: Internal Medicine - March 18, 2024 Category: Internal Medicine Authors: Fumiya Kaneko Hiroshi Suzuka Tomoaki Yoshino Ryosuke Hinosugi Source Type: research
